http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101344392-B1
Outgoing Links
Predicate | Object |
---|---|
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-216 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 |
filingDate | 2008-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2013-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2013-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | KR-101344392-B1 |
titleOfInvention | Compounds for the treatment of metabolic disorders |
abstract | Biologically active compounds of the following formula I are useful for the treatment of various metabolic disorders such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis:n n n (I)n n n Wherein n is 1 or 2; one of m and x is 0 and the other is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R 2 is alkyl having 1 to 3 carbon atoms; R 3 is hydrogen, halo, alkyl having 1 to 3 carbon atoms or alkoxy having 1 to 3 carbon atoms; One of R 4 and R 5 is alkyl having 1 to 3 carbon atoms and the other is hydrogen or alkyl having 1 to 3 carbon atoms; A is phenyl unsubstituted or substituted by halo, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and 1 or 2 groups selected from perfluoromethoxy ; Or cycloalkyl having 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; Or heteroaromatic rings having 5 or 6 atoms having 1 or 2 ring heteroatoms selected from N, S, and O and such heteroaromatic rings are covalently bonded to the remainder of the compound of formula I by ring carbon; And R 1 is hydrogen or alkyl having 1 or 2 carbon atoms. In addition, when R 1 is hydrogen, the biologically active agent may be a pharmaceutically acceptable salt of the compound of formula I.n n n n Diabetes, metabolic disorders, biologically active agents, insulin resistance syndrome |
priorityDate | 2005-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 273.